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Despite a substantial reduction in its global prevalence since 1990s, leprosy transmission 
continues unabated and remains a significant public health problem. The causes for its 
persistence are multi-factorial, ranging from the lack of implementation of contact tracing, 
the skill-dependent diagnostic method with over reliance on clinical recognition; to its 
strong linkages to social inequality and inequity. Leprosy control and elimination is still an 
enormous challenge for governments and scientists and the answer for this complex 
problem needs to be multifaceted, which includes higher research investments to identify 
risk areas, novel and better diagnostics and therapeutic tools and a reduction of social 
inequalities. 
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Leprosy is a chronic condition caused by Mycobacterium leprae that affects the skin and 
peripheral nerves which causes severe physical disability and deformity [1] with 
psychological health consequences and poor quality of life [2]. Despite a substantial 
reduction in its global prevalence from the 1990 and 2000 onwards, however, since 2005 
leprosy transmission has continued unabated and remains a significant public health 
problem that needs to be revisited. The causes of the persistence of leprosy are multi-
factorial, ranging from the infrequent implementation of contact tracing, the skill-
dependent diagnostic method and over reliance on its clinical recognition; to its strong 
linkages to social inequality and inequity. 
2. A brief history of recent elimination efforts 
In 1982 the World Health Organization (WHO) recommended the use of three antibacterial 
drugs combined, rifampicin, dapsone, and clofazimine, in response to the increasing 
numbers of dapsone-resistant cases [3]. This multidrug therapy (MDT) is more effective than 
the previous monotherapy by dapsone and its success reduced the number of prevalent 
cases and led to a decrease in the number of cases that needed to be treated at any one 
time from 5.3 million in 1985 to 3.1 million in 1991. The efficacy of MDT in reducing the 
prevalence of leprosy encouraged WHO to develop an strategy for leprosy elimination as a 
public health problem by 2000, which was defined as a prevalence of less than 1 case per 
10,000 population [4]. This global target was achieved by 2000, with a 95% reduction of 
prevalent cases, although several countries had failed to reach their national targets, 
indicating that leprosy had persisted as a public health problem in country hotspots [5]. 
Despite the rapidly declining prevalence, incidence changes were less striking, with an 
estimated 200,000 incident cases still being reported annually, of which 9-10% occur in 
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children under 15 years, indicating ongoing and recent transmission [6]. Notably, a high 
proportion of incident cases already have physical disability and deformities at the time of 
diagnosis, denoting a late diagnosis that perpetuates transmission. Moreover, given the 
large number of late diagnosis, it is likely the true number of cases is higher than the 
numbers of cases reported [7]. 
In 2016, WHO launched the 2016-2020 Global Leprosy Strategy aiming to reduce grade 2 
leprosy disability rates to less than one case per 1 million population and the number of 
leprosy-related disabilities among pediatric patients to zero [8], while maintaining the 
ultimate goal of transmission elimination of <1 new case per 10,000 population [4]. This 
strategy is reliant on the early detection and treatment of cases among high risk groups, 
although models to estimate the effectiveness of current interventions suggest that with 
the slow decline of incident cases and the substantial pool of undiagnosed cases, especially 
in endemic areas, the strategy will require many years to reach its targets [9]. 
3. The importance of contact tracing and coping methods 
The 2016-2020 Strategy also highlights the need for strengthening active case finding, 
particularly targeting leprosy foci in hyperendemic areas, to identify and treat early other 
cases occurring within the household, potentially reducing its spread and decreasing 
disability through the detection of less severe cases. Several leprosy control programs have 
implemented active case finding through mass campaigns and screen household contacts. 
Household contacts are at a higher risk of leprosy than the general population and active 
screening has a higher yield than passive case finding - when patients notice symptoms and 
seek health care services. Contact tracing has similar performance identifying cases in 
hyperendemic and low endemic areas and may also result in an earlier diagnosis, with the 
detection of cases with less disease severity [10]. Despite its higher yield, contact tracing 
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requires a skilled clinical dermato-neurological examination, which depends on the health 
worker ability and training and simpler methods that are less operator dependent are 
needed. Serological and other laboratory tests have been developed to supplement a 
clinical diagnosis, but they have either a low diagnostic accuracy, especially for PB leprosy, 
or have limitations for implementation in primary health care facilities with limited 
laboratory infrastructure [10,11]. 
Recently, the WHO recommended the use of single dose rifampicin chemoprophylaxis for 
contacts, after excluding leprosy and tuberculosis, to prevent the development of leprosy 
[10]. WHO also recommends the introduction of chemoprophylaxis by control programs, 
particularly for contacts outside the family of an index case and after adequate 
management of household contacts and consent of the index case to disclose their disease, 
as leprosy is a highly stigmatizing disease [10]. Programs are still facing challenges to 
implement this new approach, and, once implemented, it will be necessary to monitor its 
effectiveness, especially for populations at high risk for leprosy.  
A WHO position paper on the use of BCG to reduce the incidence of leprosy indicated that 
BCG at birth is effective at reducing the risk of leprosy and its use should be 
Maintained, at least in all leprosy high-burden countries or settings (good quality 
of evidence). A vaccine based on the non-pathogenic Mycobacterium indicus pranii appears 
to be protective, but evidence of its efficacy is based on only two randomized clinical trials 
(moderate quality of evidence) [10]. 
4. Challenges for leprosy diagnosis 
The diagnosis of leprosy still relies on careful dermatological and neurological examinations 
to establish sensory loss in skin lesions or reddish skin patches, thickened or enlarged 
peripheral nerves or the identification of pleomorphic acid fast bacilli on slit skin smears or 
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histopathologic changes [10]. Leprosy has varied clinical, microbiological and 
histopathological manifestations, which are determined by the bacillary load and the 
cellular immune responses to M. leprae [12,13]. This variable presentation often results in 
misdiagnosis and delayed diagnoses, especially among individuals with low bacillary loads in 
which leprosy recognition is more challenging.  
Serological and other laboratory assays currently have low sensitivity, especially in early 
disease stages and asymptomatic individuals. Although nucleic acid amplification tests (both 
single-gene and multiplex-PCR) have higher sensitivity and specificity than serological tests , 
they are difficult to perform in primary health care settings, because of their technical and 
laboratory infrastructure requirements [10,11], which contributes to a delayed diagnosis. 
Furthermore, individuals with early leprosy often have low leprosy awareness and disregard 
the symptoms, while its long history in endemic communities is associated with major fear 
of stigma, generating barriers to access health services, which compounded with the 
difficulties in diagnosis, leads to delayed diagnosis.  
5. Treatment and challenges of leprosy classification 
Similar to late diagnosis, leprosy treatment is also challenging. In 1982, WHO implemented a 
standard therapeutic regimen consisting of MDT with rifampicin, dapsone, and clofazimine, 
with doses varying with the clinical, histological and bacteriological information [3]. 
Accordingly, patients are divided into two groups: PB or MB leprosy. Patients with PB 
leprosy receive monthly rifampicin and dapsone doses and daily dapsone for 6 months. 
Patients with MB leprosy receive monthly rifampicin, dapsone and clofazimine and daily 
dapsone and clofazimine for 12 month [3]. Since this classification required laboratory 
technical expertise with well-trained professionals it was difficult to adopt by fieldworkers 
and in 1997, WHO recommended a simplified 'operational classification' based on the 
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number of skin and nerve injuries [14]. This classification has a weak to moderate 
agreement with the classification based on intra-dermal smear microscopy, with best 
outcomes achieved when using smear microscopy [13]. Despite the potential for 
misclassification, the ‘operational classification’ served the purpose of facilitating the 
allocating of patients to the MDT regimes in settings with limited technical and laboratory 
resources. 
To further simplify the therapeutic regimens, reduce the duration of treatment for MB 
leprosy and avoid the impact of misclassification, several studies have proposed a Unified 
MDT (U-MDT) using the 3-drugs for 6 months for all leprosy patients [15]. A systematic 
review of U-MDT studies reported that although PB patients could benefit from the 3-drug 
regime compared to the previous 2-drug therapy, with concern about the potential skin 
discoloration due to clofazimine use, while there is not enough evidence to support the 
recommendation to shorten the duration of treatment for MB leprosy [10]. WHO therefore 
currently recommends the use of the 3-drug rifampicin, dapsone and clofazimine regimen 
for all patients, with a treatment duration of 6 months for PB leprosy and 12 months for MB 
leprosy [10]. Further well-designed trials to better define the benefits of shortening the 
MDT regimens for MB leprosy are needed, including its effect on bacteriological outcomes 
[10].  A further complication are leprosy reactions, which are the result of exacerbated 
immune responses and occur in 25% of PB and 40% of MB leprosy. Reactions can present at 
any time, independently of treatment, including long after treatment completion [16]. The 
WHO recommends following patients for several years, as reactions can lead to further 
damage of peripheral nerves with the development of physical disability and deformities. 
Type 1 lepra reactions are delayed hypersensitivity reactions that occur in both PB and MB 
leprosy; while Type 2 lepra reactions are associated with circulation and tissue deposition of 
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immune complexes an occur only in MB leprosy. Reactions are a consequence of the disease 
and are not involved in transmission or risk of transmission and their treatment requires the 
use of analgesics and corticosteroids [16]. 
6. Socioeconomic determinants of leprosy 
Living conditions and socio-economic factors play a role enabling leprosy persistence. 
Spatiotemporal modeling and surveys have demonstrated a strong relationship between the 
persistence of leprosy and social and economic deprivation, with clusters of cases located in 
areas with high social vulnerability [17,18]. The more heterogeneous the distribution of 
resources in an area, the higher the odds that leprosy would persist as an important health 
problem [17].  
7. Conclusion and perspectives 
There is a complex interaction of factors that enables the persistence of leprosy. Here we 
highlight the challenges for an early diagnosis, for implementing contact tracing by control 
programs, and the coexistence of leprosy and social vulnerability. 
Leprosy control and elimination is still an enormous challenge and the solution for this 
complex problem needs to be multifaceted. Public policies should: i) increase research 
investment to identify risk areas, factors associated with disease progression and novel and 
better diagnostics and therapeutics; ii) investment in local health networks for the timely 
identification and treatment of patients, increasing case detection; iii) the strengthening of 
guidance and policies for national and regional programs; iv) the implementation of 
mitigating and compensatory measures for individuals affected by the disease; and v) the 
reduction of social inequalities and improved living conditions for populations with high 
leprosy burden. For now, it is still not possible to say goodbye to leprosy. 
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